Human respiratory syncytial virus and other viral infections in infants receiving palivizumab

BACKGROUND: Palivizumab is a humanized monoclonal antibody that prevents severe human respiratory syncytial virus (HRSV) infections. OBJECTIVES: We determined the etiology of respiratory viral infections in palivizumab recipients, and monitored the clinical outcome and HRSV genotype in HRSV-infected...

Descripción completa

Detalles Bibliográficos
Autores principales: Boivin, Guy, Caouette, Georges, Frenette, Line, Carbonneau, Julie, Ouakki, Manale, De Serres, Gaston
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2008
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172843/
https://www.ncbi.nlm.nih.gov/pubmed/18164233
http://dx.doi.org/10.1016/j.jcv.2007.11.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172843/
https://www.ncbi.nlm.nih.gov/pubmed/18164233
http://dx.doi.org/10.1016/j.jcv.2007.11.012

Ejemplares similares